<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Emerg Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Emerg Infect Dis</journal-id><journal-id journal-id-type="publisher-id">EID</journal-id><journal-title-group><journal-title>Emerging Infectious Diseases</journal-title></journal-title-group><issn pub-type="ppub">1080-6040</issn><issn pub-type="epub">1080-6059</issn><publisher><publisher-name>Centers for Disease Control and Prevention</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">35318928</article-id><article-id pub-id-type="pmc">8962912</article-id><article-id pub-id-type="publisher-id">21-1831</article-id><article-id pub-id-type="doi">10.3201/eid2804.211831</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research</subject></subj-group><subj-group subj-group-type="TOC-title"><subject>Unique Clinical, Immune, and Genetic Signature in Patients with Borrelial Meningoradiculoneuritis</subject></subj-group></article-categories><title-group><article-title>Unique Clinical, Immune, and Genetic Signature in Patients with Borrelial Meningoradiculoneuritis<xref rid="FN1" ref-type="fn"><sup>1</sup></xref></article-title><alt-title alt-title-type="running-head">Running Title: Borrelial Meningoradiculoneuritis </alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ogrinc</surname><given-names>Katarina</given-names></name><xref rid="FN2" ref-type="fn">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hern&#x000e1;ndez</surname><given-names>Sergio A.</given-names></name><xref rid="FN2" ref-type="fn">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Korva</surname><given-names>Mi&#x00161;a</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bogovi&#x0010d;</surname><given-names>Petra</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rojko</surname><given-names>Tereza</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lusa</surname><given-names>Lara</given-names></name></contrib><contrib contrib-type="author"><name><surname>Chiumento</surname><given-names>Geena</given-names></name></contrib><contrib contrib-type="author"><name><surname>Strle</surname><given-names>Franc</given-names></name><xref rid="FN3" ref-type="fn">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Strle</surname><given-names>Klemen</given-names></name><xref rid="FN3" ref-type="fn">
<sup>3</sup>
</xref></contrib><aff id="aff1">University Medical Center Ljubljana, Ljubljana, Slovenia (K. Ogrinc, P. Bogovi&#x0010d;, T. Rojko, F. Strle); </aff><aff id="aff2">New York State Department of Health, Albany, New York, USA (S.A. Hern&#x000e1;ndez, K. Strle); </aff><aff id="aff3">University of Ljubljana, Ljubljana (M. Korva, L. Lusa); </aff><aff id="aff4">Massachusetts Department of Public Health, Boston, Massachusetts, USA (G. Chiumento)</aff></contrib-group><author-notes><corresp id="cor1">Address for correspondence: Klemen Strle, Wadsworth Center, New York State Department of Health, 120 New Scotland Ave, Albany, NY 12201-2002, USA; email: <email xlink:href="Klemen.Strle@health.ny.gov">Klemen.Strle@health.ny.gov</email>
</corresp></author-notes><pub-date pub-type="ppub"><month>4</month><year>2022</year></pub-date><volume>28</volume><issue>4</issue><fpage>766</fpage><lpage>776</lpage><permissions><copyright-year>2022</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Preventing Chronic Disease is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.</license-p></license></permissions><abstract abstract-type="toc"><p>This form of Lyme neuroborreliosis is a distinct clinical entity with specific signs and symptoms.</p></abstract><abstract><p>Lyme neuroborreliosis (LNB) in Europe may manifest with painful meningoradiculoneuritis (also known as Bannwarth syndrome) or lymphocytic meningitis with or without cranial neuritis (peripheral facial palsy). We assessed host immune responses and the prevalence of TLR1 (toll-like receptor 1)&#x02013;1805GG polymorphism to gain insights into the pathophysiology of these conditions. Regardless of LNB manifestation, most mediators associated with innate and adaptive immune responses were concentrated in cerebrospinal fluid; serum levels were unremarkable. When stratified by specific clinical manifestation, patients with meningoradiculoneuritis had higher levels of B-cell chemoattractants CXC motif chemokine ligand (CXCL) 12 and CXCL13 and T-cell&#x02013;associated mediators CXCL9, CXCL10, and interleukin 17, compared with those without radicular pain. Moreover, these patients had a higher frequency of TLR1&#x02013;1805GG polymorphism and more constitutional symptoms. These findings demonstrate that meningoradiculoneuritis is a distinct clinical entity with unique immune and genetic pathophysiology, providing new considerations for the study of LNB and borrelial meningoradiculitis.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords: </title><kwd>Lyme disease</kwd><kwd>neuroborreliosis</kwd><kwd>meningoradiculoneuritis</kwd><kwd>peripheral facial palsy</kwd><kwd>meningitis/encephalitis</kwd><kwd>immune response</kwd><kwd>inflammation</kwd><kwd>cytokines</kwd><kwd>genetics</kwd><kwd>polymorphism</kwd><kwd>vector-borne infections</kwd><kwd>bacteria</kwd><kwd>Slovenia</kwd><kwd>United States</kwd></kwd-group></article-meta></front><body><p>Lyme borreliosis, which is caused by several species of the <italic>Borrelia burgdorferi</italic> sensu lato complex, is the most common vectorborne disease in the Northern Hemisphere. The first sign of infection is usually an expanding skin lesion, erythema migrans (EM), that appears within days or weeks at the site of the tick bite. If untreated, the infection may disseminate to involve other organ systems, including the central nervous system (CNS), heart, or joints (<xref rid="R1" ref-type="bibr"><italic>1</italic></xref>,<xref rid="R2" ref-type="bibr"><italic>2</italic></xref>).</p><p>Lyme neuroborreliosis (LNB) is the most common extracutaneous manifestation of Lyme borreliosis in Europe and the second most common such manifestation in North America (<xref rid="R1" ref-type="bibr"><italic>1</italic></xref>,<xref rid="R2" ref-type="bibr"><italic>2</italic></xref>). In Europe, LNB in adult patients typically begins as painful meningoradiculoneuritis (also known as Garin-Bujadoux-Bannwarth syndrome or Bannwarth syndrome), which is rare in the United States, or with cranial neuritis characterized by peripheral facial palsy (PFP) or lymphocytic meningitis (<xref rid="R1" ref-type="bibr"><italic>1</italic></xref>&#x02013;<xref rid="R4" ref-type="bibr"><italic>4</italic></xref>). In addition, a subset of patients experience EM and symptoms indicative of LNB (e.g., headache, vertigo, concentration disturbance), but do not fulfill the European diagnostic criteria for LNB, namely cerebrospinal fluid (CSF) pleocytosis and intrathecal borrelial antibody production (<xref rid="R5" ref-type="bibr"><italic>5</italic></xref>,<xref rid="R6" ref-type="bibr"><italic>6</italic></xref>). This subset poses a particular diagnostic and clinical challenge because the etiology of illness is often unclear.</p><p>Pathogenic mechanisms that account for different clinical manifestations of LNB are not well understood. Clinical heterogeneity in Lyme borreliosis has been largely attributed to differences in the infecting <italic>B. burgdorferi</italic> s.l. species (<xref rid="R1" ref-type="bibr"><italic>1</italic></xref>,<xref rid="R2" ref-type="bibr"><italic>2</italic></xref>). In Europe, LNB is caused predominantly by <italic>B. garinii</italic> (and closely related <italic>B. bavariensis</italic>) but only rarely by <italic>B. afzelii</italic>, which is associated with skin manifestations, or <italic>B. burgdorferi</italic> sensu stricto, which is highly arthritogenic, implying a strong species-specific imprinting of clinically evidenced disease (<xref rid="R1" ref-type="bibr"><italic>1</italic></xref>,<xref rid="R2" ref-type="bibr"><italic>2</italic></xref>,<xref rid="R7" ref-type="bibr"><italic>7</italic></xref>,<xref rid="R8" ref-type="bibr"><italic>8</italic></xref>). However, although <italic>B. garinii</italic> has particular proclivity for the central nervous system (CNS) and undoubtedly serves as the initial trigger of LNB, Lyme borreliae do not express any known toxins that cause disease. Rather, the host immune response, which is shaped by various <italic>Borrelia</italic> species (<xref rid="R9" ref-type="bibr"><italic>9</italic></xref>&#x02013;<xref rid="R13" ref-type="bibr"><italic>13</italic></xref>), is thought to be a key determinant of the clinical signs and symptoms of Lyme borreliosis, including LNB.</p><p>In addition to infection with a particular <italic>Borrelia</italic> species or strain, the immune responses are further augmented by alterations in the human genome. We have previously demonstrated that a single-nucleotide polymorphism (SNP; 1805GG) in the host toll-like receptor 1 (TLR1), a key pathogen sensing receptor for borrelia, is associated with more symptomatic early Lyme borreliosis and a greater frequency of postantibiotic, chronic inflammatory Lyme arthritis (<xref rid="R12" ref-type="bibr"><italic>12</italic></xref>,<xref rid="R14" ref-type="bibr"><italic>14</italic></xref>). This TLR1&#x02013;1805GG SNP is associated with severe disease presumably because it enables maladaptive immune responses; EM patients with the TLR1&#x02013;1805GG SNP had substantially higher levels of pro-inflammatory cytokines and chemokines in blood compared with those without the SNP. Moreover, in patients with Lyme arthritis, this SNP was associated with exceptionally high levels of the interferon (IFN) &#x003b3; and IFN-&#x003b3;&#x02013;associated mediators CXC motif chemokine ligand (CXCL) 9 and CXCL10 in synovial fluid, supporting the predominant cellular and inflammatory T-helper 1 (Th1) responses in joints in these patients. Thus, host immune response, which is shaped by both microbial and host genetics, is a key driver of the clinical heterogeneity in Lyme borreliosis in general and probably in LNB, although this has not been tested directly.</p><p>Several studies in Europe and the United States have characterized host immune responses in patients with LNB in an effort to gain insights into pathogenesis and to identify biomarkers to aid in diagnosis (<xref rid="R15" ref-type="bibr"><italic>15</italic></xref>&#x02013;<xref rid="R18" ref-type="bibr"><italic>18</italic></xref>). These studies demonstrated the activation of a broad-ranging innate and adaptive immune response in patients with LNB. In particular, LNB patients have marked CSF levels of CXCL13, a B-cell chemoattractant, compared with patients with other neurologic conditions (<xref rid="R15" ref-type="bibr"><italic>15</italic></xref>&#x02013;<xref rid="R19" ref-type="bibr"><italic>19</italic></xref>), prompting the use of CXCL13 as an adjunct diagnostic biomarker of LNB (<xref rid="R19" ref-type="bibr"><italic>19</italic></xref>&#x02013;<xref rid="R26" ref-type="bibr"><italic>26</italic></xref>). However, the role of host immunity in the pathogenesis of clinically distinct LNB manifestations and the possibility that these outcomes are associated with specific host genetic predisposition has not been explored.</p><p>We investigated the role of innate and adaptive immune responses and the TLR1&#x02013;1805GG SNP in specific clinical manifestations of LNB. Our findings demonstrate that borrelial meningoradiculoneuritis is a distinct clinical entity with unique immune and genetic pathophysiology and offer new insights into the pathogenesis and diagnosis of this condition.</p><sec sec-type="methods"><title>Methods</title><sec><title>Patient Selection</title><p>This study is based on 61 adult patients who met the modified European diagnostic criteria for LNB (<xref rid="R5" ref-type="bibr"><italic>5</italic></xref>), defined by the presence of symptoms suggestive of neurologic involvement; CSF lymphocytic pleocytosis; demonstration of borrelial infection with intrathecal synthesis of borrelia antibodies (IT-Bb-Abs), isolation of borreliae from CSF; or presence of EM. For comparison, we included 59 patients with signs and symptoms indicative of LNB but without pleocytosis and termed them suspected LNB. All patients were seen at the Lyme borreliosis outpatient clinic by the same clinical team in the Department of Infectious Diseases, University Medical Center Ljubljana, Ljubljana, Slovenia, during 2006&#x02013;2013. The Medical Ethics Committee of the Ministry of Health, Republic of Slovenia (no. 35/08/06), and the Institutional Review Board of the New York Department of Health (IRB protocol no. 20-013) approved the study.</p></sec><sec><title>Clinical Evaluation</title><p>We collected clinical and demographic information using a structured questionnaire as described previously (<xref rid="R3" ref-type="bibr"><italic>3</italic></xref>). In addition to their general medical history, patients were asked about tick bites, EM, and new onset or worsening of symptoms. We also assessed signs indicative of neurologic involvement (meningeal signs, PFP, other cranial nerve palsy, sensory or motor deficits, tremor) and the presence of EM (<xref rid="R27" ref-type="bibr"><italic>27</italic></xref>). We subsequently grouped patients into 3 categories according to clinical and diagnostic criteria: 1) painful meningoradiculoneuritis accompanied by CSF pleocytosis; 2) LNB without radicular pain, consisting of PFP with CSF pleocytosis or lymphocytic meningitis without cranial neuritis (PFP/meningitis); and 3) suspected LNB with EM and neurologic symptoms suggestive of LNB, but normal CSF cell counts (<xref rid="R3" ref-type="bibr"><italic>3</italic></xref>,<xref rid="R6" ref-type="bibr"><italic>6</italic></xref>). Serum and CSF samples were obtained at first visit, usually before antimicrobial therapy, and stored at &#x02212;80&#x000b0;C for subsequent analyses.</p></sec><sec><title>Laboratory Evaluation</title><p>We defined CSF pleocytosis as a leukocyte count &#x0003e;5 &#x000d7; 10<sup>6</sup> cells/L. We determined IgM and IgG levels against <italic>B. burgdorferi</italic> s.l. in serum and CSF with indirect chemiluminescence immunoassay using recombinant OspC and VlsE antigens (LIAISON; Diasorin, <ext-link xlink:href="https://www.diasorin.com" ext-link-type="uri">https://www.diasorin.com</ext-link>). We assessed intrathecal synthesis of <italic>Borrelia</italic> IgG as described previously (<xref rid="R28" ref-type="bibr"><italic>28</italic></xref>); antibody index values &#x0003e;1.4 were indicative of IT-Abs against <italic>B. burgdorferi</italic> s.l. We cultivated <italic>Borrelia</italic> in CSF as reported previously (<xref rid="R29" ref-type="bibr"><italic>29</italic></xref>&#x02013;<xref rid="R31" ref-type="bibr"><italic>31</italic></xref>).</p></sec><sec><title>Cytokine and Chemokine Determinations</title><p>We assessed the levels of 17 mediators associated with innate (CC motif chemokine ligand [CCL] 2, CCL3, CCL4, interleukin [IL] 8, IL-10, tumor necrosis factor, IFN-&#x003b1;), and adaptive T-cell (T<sub>H</sub>1, IFN-&#x003b3;, CXCL9, CXCL10; T<sub>H</sub>17, IL-17A, IL-21, IL-23; CCL19, CCL21) or B-cell (CXCL12, CXCL13) immune responses. We tested for these levels in matched patient serum and CSF samples using bead-based multiplex assays (EMD Millipore, <ext-link xlink:href="https://www.emdmillipore.com" ext-link-type="uri">https://www.emdmillipore.com</ext-link>) coupled with the Luminex-200 Analyzer (Luminex, <ext-link xlink:href="https://www.luminexcorp.com" ext-link-type="uri">https://www.luminexcorp.com</ext-link>). We quantified each inflammatory mediator in all samples in one complete experiment to minimize sample freeze-thaw and assay variation. We then stratified cytokine and chemokine levels according to clinical and laboratory findings in the same patients.</p></sec><sec><title>TLR1&#x02013;1805 Genotyping</title><p>We determined TLR1&#x02013;1805 genotypes (TT, TG, GG; G denotes the SNP) using PCR amplification followed by restriction fragment length polymorphism (RFLP) as described previously (<xref rid="R12" ref-type="bibr"><italic>12</italic></xref>). In brief, we extracted total DNA from patients&#x02019; blood (QIAamp DNA Blood Mini Kit; QIAGEN, <ext-link xlink:href="https://www.qiagen.com" ext-link-type="uri">https://www.qiagen.com</ext-link>) and amplified it using specific primers: forward: 5&#x02032;-GCAGGGGACAATCCATTCCAA-3&#x02032;; reverse: 5&#x02032;CCCAGAAAGAATCGTGCCCA-3&#x02032; (IDT). Each reaction contained 0.4 &#x000b5;M forward/reverse primers, 2 &#x000b5;L DNA (&#x02265;50 ng), and 2XDreamTaq PCR Master Mix (ThermoFisher Scientific, <ext-link xlink:href="https://www.thermofisher.com" ext-link-type="uri">https://www.thermofisher.com</ext-link>). PCR amplicons were digested with <italic>Pst</italic>I enzyme (New England BioLabs, <ext-link xlink:href="https://www.neb.com" ext-link-type="uri">https://www.neb.com</ext-link>) and visualized by electrophoresis (1.5% agarose gel, GelRed nucleic acid stain). We determined TLR1&#x02013;1805 genotype in 65 patients with confirmed LNB (meningoradiculoneuritis, n = 40; LNB without radiculoneuritis [termed PFP/meningitis], n = 25) and for comparison in 71 EM patients without neurologic involvement. Because of the requirement for consent for genetic studies, these 65 LNB patients represent a different cohort from the 61 patients assessed in the rest of the study. In addition, we ascertained TLR1&#x02013;1805 genotype in the general European population (n = 503) by datamining the Ensembl genome browser 104 (<ext-link xlink:href="https://useast.ensembl.org/index.html" ext-link-type="uri">https://useast.ensembl.org/index.html</ext-link>).</p></sec><sec><title>Statistical Analyses</title><p>We evaluated categorical variables (presence/absence of symptoms or TLR1-SNP) using Fisher exact test. We assessed quantitative variables (number of symptoms, cytokine levels) using Mann-Whitney nonparametric rank-sum test in Prism version 9.1.1 (<ext-link xlink:href="https://www.graphpad.com" ext-link-type="uri">https://www.graphpad.com</ext-link>). We applied Spearman correlation for cytokine associations. We adjusted for multiple comparisons using the Benjamini-Hochberg test; we set the false discovery rate (FDR) to 0.05 and considered p<underline>&#x0003c;</underline>0.05 statistically significant.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Clinical Characteristics According to LNB Presentation</title><p>Of the 120 patients in this study, 19 had meningoradiculoneuritis, 42 had LNB without radiculoneuritis (PFP/meningitis; 35 PFP, 7 lymphocytic meningitis), and 59 were classified as suspected LNB because they had clinical signs and symptoms indicative of LNB (EM with neurologic symptoms) but lacked CSF pleocytosis (<xref rid="R5" ref-type="bibr"><italic>5</italic></xref>) (<xref rid="T1" ref-type="table">Table 1</xref>). Seventy-two participants were female (60%) and 48 male (40%); median age was 51 years. When stratified by specific clinical presentation, patients with meningoradiculoneuritis were more likely to have had an EM skin lesion during the course of disease than LNB patients without radicular pain (68% vs. 24%; p = 0.004). Meningoradiculoneuritis patients had more symptoms than LNB patients without radiculitis (median 6 vs. 3 symptoms; p&#x0003c;0.001) and their symptoms lasted longer (30 days vs. 10 days; p<underline>&#x0003c;</underline>0.001). Meningoradiculoneuritis patients had more symptoms (median 6 vs. 4 symptoms; p = 0.01) and symptoms of longer duration (30 vs. 16 days; p<underline>&#x0003c;</underline>0.03) than patients with suspected LNB. Of the 13 constitutional symptoms we assessed, patients with meningoradiculoneuritis had a higher frequency of 8 specific symptoms, 4 of which reached statistical significance (<xref rid="F1" ref-type="fig">Figure 1</xref>). The most common symptoms were sleep disturbance, headache, and fatigue.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><title>Clinical characteristics of patients with confirmed or suspected Lyme neuroborreliosis, Ljubljana, Slovenia, 2006&#x02013;2013* </title></caption><table frame="hsides" rules="groups"><col width="166" span="1"/><col width="67" span="1"/><col width="63" span="1"/><col width="63" span="1"/><col width="40" span="1"/><col width="40" span="1"/><col width="41" span="1"/><thead><tr><th rowspan="2" valign="bottom" align="left" scope="col" colspan="1">Characteristic</th><th rowspan="2" valign="bottom" align="center" scope="col" colspan="1">MR, n = 19</th><th rowspan="2" valign="bottom" align="center" scope="col" colspan="1">PFP/meningitis, n = 42</th><th rowspan="2" valign="bottom" align="center" scope="col" colspan="1">Suspected LNB, n = 59</th><th valign="bottom" colspan="3" align="center" scope="colgroup" rowspan="1">p value&#x02020;<hr/></th></tr><tr><th valign="bottom" colspan="1" align="center" scope="colgroup" rowspan="1">MR vs. PFP&#x02021;</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">MR vs. sLNB</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">PFP&#x02021; vs. sLNB</th></tr></thead><tbody><tr><td colspan="7" valign="top" align="left" scope="col" rowspan="1">Demographics</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Age, y</td><td valign="top" align="center" rowspan="1" colspan="1">51 (21&#x02013;73)</td><td valign="top" align="center" rowspan="1" colspan="1">52 (15&#x02013;81)</td><td valign="top" align="center" rowspan="1" colspan="1">51 (25&#x02013;83)</td><td valign="top" align="center" rowspan="1" colspan="1">0.4</td><td valign="top" align="center" rowspan="1" colspan="1">0.8</td><td valign="top" align="center" rowspan="1" colspan="1">0.4</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Sex</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> F </td><td valign="top" align="center" rowspan="1" colspan="1">9 (47)</td><td valign="top" align="center" rowspan="1" colspan="1">17 (40)</td><td valign="top" align="center" rowspan="1" colspan="1">45 (76)</td><td valign="top" align="center" rowspan="1" colspan="1">0.8</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.02</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.0004</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> M</td><td valign="top" align="center" rowspan="1" colspan="1">10 (53)</td><td valign="top" align="center" rowspan="1" colspan="1">25 (60)</td><td valign="top" align="center" rowspan="1" colspan="1">14 (24)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;No. tick bites/y<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">1 (0&#x02013;17)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 (0&#x02013;20)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">2 (0&#x02013;30)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.9<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.7<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.5<hr/></td></tr><tr><td colspan="7" valign="top" align="left" scope="col" rowspan="1">Clinical characteristics</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Current or recent EM</td><td valign="top" align="center" rowspan="1" colspan="1">13 (68)</td><td valign="top" align="center" rowspan="1" colspan="1">10 (24)</td><td valign="top" align="center" rowspan="1" colspan="1">59 (100)&#x000a7;</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.004</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.0001</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Solitary EM</td><td valign="top" align="center" rowspan="1" colspan="1">12 (63)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (14)</td><td valign="top" align="center" rowspan="1" colspan="1">53 (90)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.0007</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.01</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Multiple EM</td><td valign="top" align="center" rowspan="1" colspan="1">1 (5)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (10)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (10)</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">1</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> EM duration, d</td><td valign="top" align="center" rowspan="1" colspan="1">35 (6&#x02013;128)</td><td valign="top" align="center" rowspan="1" colspan="1">11 (3&#x02013;60)</td><td valign="top" align="center" rowspan="1" colspan="1">21 (1&#x02013;240)</td><td valign="top" align="center" rowspan="1" colspan="1">0.2</td><td valign="top" align="center" rowspan="1" colspan="1">0.9</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.01</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No. symptoms/patient</td><td valign="top" align="center" rowspan="1" colspan="1">6 (1&#x02013;12)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (1&#x02013;10)</td><td valign="top" align="center" rowspan="1" colspan="1">4 (1&#x02013;13)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.01</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.001</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Duration of symptoms, d</td><td valign="top" align="center" rowspan="1" colspan="1">30 (7&#x02013;75)</td><td valign="top" align="center" rowspan="1" colspan="1">10 (3&#x02013;365)</td><td valign="top" align="center" rowspan="1" colspan="1">16 (2&#x02013;270)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.001</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">0.2</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.03</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Radicular pain</td><td valign="top" align="center" rowspan="1" colspan="1">19 (100%)</td><td valign="top" align="center" rowspan="1" colspan="1">0 (0%)</td><td valign="top" align="center" rowspan="1" colspan="1">9 (15%)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.01</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Peripheral facial palsy<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">9 (47%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">35 (83%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0 (0%)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.01</bold>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
<hr/>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
<hr/>
</td></tr><tr><td colspan="7" valign="top" align="left" scope="col" rowspan="1">CSF findings</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Pleocytosis</td><td valign="top" align="center" rowspan="1" colspan="1">19 (100)</td><td valign="top" align="center" rowspan="1" colspan="1">42 (100)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">1.0</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Leukocyte count, &#x000d7; 10<sup>6</sup> cells/L</td><td valign="top" align="center" rowspan="1" colspan="1">160 (15&#x02013;886)</td><td valign="top" align="center" rowspan="1" colspan="1">56 (6&#x02013;1579)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (0&#x02013;4)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.005</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;Lymphocyte count no. &#x000d7; 10<sup>6</sup> cells/L</td><td valign="top" align="center" rowspan="1" colspan="1">144 (15&#x02013;811)</td><td valign="top" align="center" rowspan="1" colspan="1">47 (4&#x02013;1477)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (0&#x02013;4)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.005</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#x000a0;&#x000a0;<italic>Borrelia</italic> culture positivity&#x000b6;</td><td valign="top" align="center" rowspan="1" colspan="1">4 (21)</td><td valign="top" align="center" rowspan="1" colspan="1">3 (7)</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">0.2</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.002</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">0.06</td></tr></tbody></table><table-wrap-foot><p>*Values are no. (%) or median (range). CSF, cerebrospinal fluid; EM, erythema migrans; LNB, Lyme neuroborreliosis; MR, meningoradiculoneuritis; PFP, peripheral facial palsy; sLNB, suspected Lyme neuroborreliosis.
&#x02020;Statistical analyses were performed using Mann-Whitney nonparametric rank sum test. Median values are shown. Bold type indicates statistically significant p values after Benjamini-Hochberg correction for multiple comparisons (false discovery rate =&#x000a0;0.05).
&#x02021;PFP group includes 42 LNB patients without radicular pain (35 patients with PFP and 7 with lymphocytic meningitis).
&#x000a7;Presence of EM was a criterion for suspected LNB.
&#x000b6;<italic>Borrelia burgdorferi</italic> sensu lato positive culture result in CSF.</p></table-wrap-foot></table-wrap><fig position="float" id="F1" fig-type="figure"><label>Figure 1</label><caption><p>Frequency of individual signs and symptoms at study enrollment among patients with LNB treated in Ljubljana, Slovenia, during 2006&#x02013;2013. Patients were stratified into 3 groups: meningoradiculoneuritis, PFP/meningitis without radicular pain, or patients with suspected LNB who had EM and signs and symptoms suggestive of LNB but did not meet the standard diagnostic criteria. *Meningoradiculoneuritis vs. PFP/meningitis, p&#x0003c;0.05; &#x02020;meningoradiculoneuritis vs. suspected LNB, p&#x0003c;0.005. LNB, Lyme neuroborreliosis; PFP, peripheral facial palsy.</p></caption><graphic xlink:href="21-1831-F1" position="float"/></fig></sec><sec><title>Immune Responses in Serum and CSF</title><p>In 61 patients with confirmed LNB (meningoradiculoneuritis or PFP/meningitis), most cytokines and chemokines associated with adaptive T-cell and B cell immune responses were more highly concentrated in CSF, the site of disease, than in serum (<xref rid="T2" ref-type="table">Table 2</xref>). This finding was particularly apparent for IFN-&#x003b3;&#x02013;inducible chemokines CXCL9 (median 347 vs. 170 pg/mL; p = 0.02) and CXCL10 (median&#x000a0;4,139 vs. 143 pg/mL; p&#x0003c;0.001) which recruit CD4+ T cells, as well as B-cell chemoattractants CXCL12 (median 1,541 vs. 820 pg/mL; p&#x0003c;0.001) and CXCL13 (median 352 vs. 9 pg/mL; p&#x0003c;0.001) which recruit B cells to site of infection. In contrast, mediators associated with innate and Th17 immune responses were present at lower overall concentrations and often at similar levels in serum and CSF (<xref rid="T2" ref-type="table">Table 2</xref>).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><title>Immune mediators in cerebrospinal fluid and serum in 61 confirmed patients with Lyme neuroborreliosis, Ljubljana, Slovenia, 2006&#x02013;2013*</title></caption><table frame="hsides" rules="groups"><col width="54" span="1"/><col width="78" span="1"/><col width="59" span="1"/><col width="38" span="1"/><thead><tr><th valign="bottom" align="left" scope="col" rowspan="1" colspan="1">Cytokine or chemokine</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">CSF, pg/mL</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">Serum, pg/mL</th><th valign="bottom" align="center" scope="col" rowspan="1" colspan="1">p value&#x02020;</th></tr></thead><tbody><tr><td colspan="4" valign="top" align="left" scope="col" rowspan="1">Innate</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> IL-8</td><td valign="top" align="center" rowspan="1" colspan="1"><bold>39</bold> (8&#x02013;289)</td><td valign="top" align="center" rowspan="1" colspan="1"><bold>8</bold> (0&#x02013;473)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> IL-10</td><td valign="top" align="center" rowspan="1" colspan="1"><bold>0.3</bold> (0&#x02013;54)</td><td valign="top" align="center" rowspan="1" colspan="1"><bold>0.3</bold> (0&#x02013;28)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.0001</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> TNF</td><td valign="top" align="center" rowspan="1" colspan="1">5 (1&#x02013;54)</td><td valign="top" align="center" rowspan="1" colspan="1">7 (0&#x02013;170)</td><td valign="top" align="center" rowspan="1" colspan="1">0.3</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> IFN-&#x003b1;</td><td valign="top" align="center" rowspan="1" colspan="1"><bold>88</bold> (0&#x02013;406)</td><td valign="top" align="center" rowspan="1" colspan="1"><bold>22</bold> (0&#x02013;205)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> CCL2</td><td valign="top" align="center" rowspan="1" colspan="1"><bold>343</bold> (71&#x02013;10,000)</td><td valign="top" align="center" rowspan="1" colspan="1"><bold>213</bold> (7&#x02013;516)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> CCL3</td><td valign="top" align="center" rowspan="1" colspan="1">5 (0.3&#x02013;16)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (0.3&#x02013;227)</td><td valign="top" align="center" rowspan="1" colspan="1">0.07</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> CCL4<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>5</bold> (0.3&#x02013;139)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1"><bold>20</bold> (0.3&#x02013;221)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
<hr/>
</td></tr><tr><td colspan="4" valign="top" align="left" scope="col" rowspan="1">T-cell adaptive</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> IFN&#x003b3;</td><td valign="top" align="center" rowspan="1" colspan="1">2 (0&#x02013;77)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (0&#x02013;25)</td><td valign="top" align="center" rowspan="1" colspan="1">0.3</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> CXCL9</td><td valign="top" align="center" rowspan="1" colspan="1"><bold>347</bold> (4&#x02013;6833)</td><td valign="top" align="center" rowspan="1" colspan="1"><bold>170</bold> (2&#x02013;3,508)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.02</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> CXCL10</td><td valign="top" align="center" rowspan="1" colspan="1"><bold>4,139</bold> (156&#x02013;46,025)</td><td valign="top" align="center" rowspan="1" colspan="1"><bold>143</bold> (3&#x02013;932)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> IL-17</td><td valign="top" align="center" rowspan="1" colspan="1"><bold>3</bold> (0&#x02013;8)</td><td valign="top" align="center" rowspan="1" colspan="1"><bold>2</bold> (0&#x02013;25)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.02</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> IL-23</td><td valign="top" align="center" rowspan="1" colspan="1"><bold>2</bold> (2&#x02013;33)</td><td valign="top" align="center" rowspan="1" colspan="1"><bold>2</bold> (2&#x02013;4,949)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>0.01</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> GM-CSF</td><td valign="top" align="center" rowspan="1" colspan="1"><bold>5</bold> (0&#x02013;22)</td><td valign="top" align="center" rowspan="1" colspan="1"><bold>3</bold> (0&#x02013;22)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> CCL19</td><td valign="top" align="center" rowspan="1" colspan="1"><bold>84</bold> (19&#x02013;768)</td><td valign="top" align="center" rowspan="1" colspan="1"><bold>28</bold> (2&#x02013;143)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> CCL21<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">17 (17&#x02013;241)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">17 (17&#x02013;541)<hr/></td><td valign="top" align="center" rowspan="1" colspan="1">0.7<hr/></td></tr><tr><td colspan="4" valign="top" align="left" scope="col" rowspan="1">B-cell adaptive</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> CXCL12</td><td valign="top" align="center" rowspan="1" colspan="1"><bold>1,541</bold> (89&#x02013;5,518)</td><td valign="top" align="center" rowspan="1" colspan="1"><bold>820</bold> (89&#x02013;4184)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> CXCL13</td><td valign="top" align="center" rowspan="1" colspan="1"><bold>352</bold> (1&#x02013;76,869)</td><td valign="top" align="center" rowspan="1" colspan="1"><bold>9</bold> (1&#x02013;66)</td><td valign="top" align="center" rowspan="1" colspan="1">
<bold>&#x0003c;0.0001</bold>
</td></tr></tbody></table><table-wrap-foot><p>*Values are median (range). CCL, CC motif chemokine ligand; CSF, cerebrospinal fluid; CXCL, CXC motif chemokine ligand; IL, interleukin; IFN, interferon; TNF, tumor necrosis factor.
&#x02020;Statistical analyses were performed using Mann-Whitney non-parametric rank sum test. Bold type indicates statistically significant p values after Benjamini-Hochberg correction for multiple comparisons (false discovery rate FDR&#x000a0;=&#x000a0;0.05).</p></table-wrap-foot></table-wrap></sec><sec><title>Immune Responses According to LNB Presentation</title><p>To determine if patients with different clinical presentations of LNB carry distinct immune signatures, we stratified cytokine and chemokine levels in CSF into 3 groups: meningoradiculoneuritis (n = 19), PFP/meningitis (n = 42), and suspected LNB (n = 59). Heat map analyses of global immune responses revealed that patients with meningoradiculoneuritis have the highest levels of most mediators tested; those with PFP/meningitis have intermediate levels, and those with suspected LNB have the lowest levels (<xref rid="F2" ref-type="fig">Figure 2</xref>, panel A). We obtained similar results using unguided hierarchical clustering (<xref rid="F2" ref-type="fig">Figure 2</xref>, panel B). Patients with meningoradiculoneuritis clustered primarily with the highest cytokine and chemokine levels and largest CSF leukocyte counts, whereas those with suspected LNB clustered with the lowest cytokine and chemokine levels and CSF leukocyte counts. Patients with PFP/meningitis were more interspersed. We observed these trends for cytokines and chemokines associated with both innate and adaptive immune responses.</p><fig position="float" id="F2" fig-type="figure"><label>Figure 2</label><caption><p>Heat map analysis of inflammatory mediators in CSF stratified by clinical presentation of LNB among patients with Lyme neuroborreliosis treated in Ljubljana, Slovenia, during 2006&#x02013;2013. A) Levels of inflammatory mediators stratified by LNB manifestation. B) Hierarchical clustering analysis (Euclidian distance) of inflammatory mediators and CSF leukocyte counts. We assessed the levels of 17 cytokines and chemokines associated with innate and adaptive (T- and B-cell) responses in CSF of patients with meningoradiculoneuritis, PFP/meningitis, or suspected LNB. Each column represents an individual patient, with the corresponding mediators along the different rows. Heat map was constructed using Morpheus software (<ext-link xlink:href="https://software.broadinstitute.org/morpheus" ext-link-type="uri">https://software.broadinstitute.org/morpheus</ext-link>). In the case of IFN-&#x003b1;, 3 values were exceptionally low (at lower limit of detection), resulting in disproportionately intense red coloring of other values. CSF, cerebrospinal fluid; CXCL, CXC motif chemokine ligand; GM-CSF, granulocyte macrophage colony&#x02013;stimulating factor; IL, interleukin; IFN, interferon; LNB, Lyme neuroborreliosis; MIP, macrophage inflammatory protein; PFP, peripheral facial palsy; TNF, tumor necrosis factor.</p></caption><graphic xlink:href="21-1831-F2" position="float"/></fig><p>We identified through statistical analyses 8 cytokines and chemokines with significant differences between groups (<xref rid="F3" ref-type="fig">Figure 3</xref>), including mediators associated with innate (IL-8, IL-10, CCL3), and adaptive T-cell (CXCL9, CXCL10, IL-17) and B-cell (CXCL12, CXCL13) immune responses. We observed the highest levels and most pronounced differences between groups for B-cell chemoattractants CXCL12 (median values for meningoradiculoneuritis groups, 2,568 pg/mL; for PFP/meningitis, 1,170 pg/mL; for suspected LNB, 819 pg/mL) and CXCL13 (meningoradiculoneuritis, 1,000 pg/mL; PFP/meningitis, 53 pg/mL; suspected LNB, 1 pg/mL) and for T-cell chemoattractants CXCL9 (meningoradiculoneuritis, 680 pg/mL; PFP/meningitis, 252 pg/mL; suspected LNB 15 pg/mL) and CXCL10 (meningoradiculoneuritis, 5,159 pg/mL; PFP/meningitis, 4,087 pg/mL; suspected LNB, 236 pg/mL). These mediators correlated strongly with leukocyte counts in CSF (p&#x0003c;0.001) (<xref rid="F4" ref-type="fig">Figure 4</xref>), implying the predominance of CSF-localized T- and B-cell responses in meningoradiculoneuritis.</p><fig position="float" id="F3" fig-type="figure"><label>Figure 3</label><caption><p>Statistical correlation of the levels of 8 immune mediators in CSF, by clinical manifestation, among patients with LNB treated in Ljubljana, Slovenia, during 2006&#x02013;2013. A) Mediators associated with innate response are IL-8, IL-10, and CCL3. B) Mediators associated with T-cell adaptive response are CXCL9, CXCL10, and IL-18. C) Mediators associated with B-cell adaptive response are CXCL12 and CXCL13. Black circles represent meningoradiculoneuritis (n = 19); white circles, PFP/meningitis (n = 42); and white squares, suspected LNB (n = 59). Horizontal lines represent median values. Statistical analyses were performed using nonparametric Mann-Whitney rank sum test. p values indicate largest differences for individual patients among groups. CCL, CC motif chemokine ligand; CSF, cerebrospinal fluid; CXCL, CXC motif chemokine ligand; IL, interleukin; LNB, Lyme neuroborreliosis; PFP, peripheral facial palsy. </p></caption><graphic xlink:href="21-1831-F3" position="float"/></fig><fig position="float" id="F4" fig-type="figure"><label>Figure 4</label><caption><p>Correlation between the levels of 5 inflammatory mediators in CSF and CSF leukocyte counts among 120 patients with Lyme neuroborreliosis treated in Ljubljana, Slovenia, during 2006&#x02013;2013. A) CXCL9; B) CXCL10; C) IL-17; D) CXCL12; E) CXCL13. Solid lines inside the graph represent linear regression; dotted lines indicate 95% CIs. &#x003c1; and p values were derived using the Spearman correlation. CSF, cerebrospinal fluid. </p></caption><graphic xlink:href="21-1831-F4" position="float"/></fig></sec><sec><title>Frequency of TLR1&#x02013;1805GG Polymorphism in LNB</title><p>We previously demonstrated that the TLR1&#x02013;1805GG SNP is associated with excessive immune responses, more symptomatic early infection, and a heightened risk for chronic inflammatory (antibiotic-refractory) Lyme arthritis, thereby linking host genetic variation with dysregulated immunity and severe Lyme borreliosis (<xref rid="R12" ref-type="bibr"><italic>12</italic></xref>). Herein, we extended these findings to LNB (<xref rid="F5" ref-type="fig">Figures 5</xref>, <xref rid="F6" ref-type="fig">6</xref>). As reported previously (<xref rid="R12" ref-type="bibr"><italic>12</italic></xref>), 49% of the general population of Europe had both copies of the SNP (GG); distribution was similar in female and male patients. Similarly, 51% of patients with EM had both copies of the SNP, whereas the frequency was slightly higher in patients with LNB (57%), but these differences were not statistically significant (<xref rid="F5" ref-type="fig">Figure 5</xref>). However, when we subcategorized LNB patients by clinical presentation, patients with meningoradiculoneuritis had a significantly higher frequency of TLR1&#x02013;1805GG SNP compared to patients with PFP/meningitis (68% vs. 40%; odds ratio 3.1; p = 0.04) (<xref rid="F6" ref-type="fig">Figure 6</xref>). Consent for genetic studies was not obtained from patients with suspected LNB, and they were not included in these analyses.</p><fig position="float" id="F5" fig-type="figure"><label>Figure 5</label><caption><p>Frequency of TLR1&#x02013;1805GG polymorphism among patients with Lyme borreliosis treated in Ljubljana, Slovenia, during 2006&#x02013;2013 (A), compared with the general population of Europe (B). A) Lyme borreliosis patients with EM vs. LNB; B) general population by female vs. male sex. The TLR1 SNP results in an exchange of thymine (T, ancestral) with a guanine (G) allele at position 1805; GG corresponds to both copies of the SNP allele (SNP), TG with one copy (heterozygous), and TT with no copies (ancestral). The information in the general population was obtained from Ensemble genome browser 104 and is based on data from the 1,000 Genomes Project (<ext-link xlink:href="https://useast.ensembl.org/index.html" ext-link-type="uri">https://useast.ensembl.org/index.html</ext-link>). EM, erythema migrans; LNB, Lyme neuroborreliosis; SNP, single-nucleotide polymorphism. </p></caption><graphic xlink:href="21-1831-F5" position="float"/></fig><fig position="float" id="F6" fig-type="figure"><label>Figure 6</label><caption><p>Frequency of TLR1&#x02013;1805 genotypes, stratified by clinical manifestations (meningoradiculoneuritis and PFP/meningitis) among patients with Lyme neuroborreliosis treated in Ljubljana, Slovenia, during 2006&#x02013;2013. The frequency of TLR1&#x02013;1805 genotypes was determined via PCR restriction fragment-length polymorphism. Statistical analyses were performed using Fisher exact test for categorical variables or odds ratios. PFP, peripheral facial palsy; SNP, single-nucleotide polymorphism. </p></caption><graphic xlink:href="21-1831-F6" position="float"/></fig></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>CNS involvement is a common manifestation of Lyme borreliosis in Europe. Although distinct manifestations of LNB are well described clinically, the reasons for these differences are not well understood. Herein, we demonstrated that LNB patients with meningoradiculoneuritis have a different immune signature than LNB patients without radiculoneuritis. Although both LNB groups (patients with meningoradiculoneuritis and PFP/meningitis) have broadly elevated innate and adaptive inflammatory immune response that the suspected LNB group does not, we observed the most dramatic differences for cytokines and chemokines associated with adaptive T- and B-cell immune responses in CSF. In particular, patients with meningoradiculoneuritis had the highest CSF levels of B-cell chemoattractants CXCL12 and CXCL13, as well as T-cell chemoattractants CXCL9 and CXCL10, and a potent Th17 cytokine, IL-17. These inflammatory mediators were often concentrated 10- to 50-fold in CSF, the site of the disease, and correlated strongly with lymphocyte counts (p&#x0003c;0.001), implying a role in CNS inflammation and disease pathogenesis. In contrast, cytokine and chemokine levels did not correlate with symptom duration, implying that greater immune responses are not caused simply by the longer disease duration in patients with meningoradiculoneuritis. Rather, we postulate that these site-specific T- and B-cell responses likely play a direct role in the pathophysiology of meningoradiculoneuritis and the higher prevalence of systemic symptoms in this condition. T- and B-cell mediators, namely IL-17 and CXCL13, have been implicated in disease pathogenesis in a recent study of patients with LNB or suspected LNB in Sweden (<xref rid="R32" ref-type="bibr"><italic>32</italic></xref>), although that study did not compare patients with distinct manifestations of LNB. In contrast to findings for CSF, we observed low levels of most of the immune mediators in serum in LNB patients that were comparable to the levels in healthy persons (data not shown). Collectively, these findings support the role of site-specific T- and B-cell responses in the pathogenesis of borrelial meningoradiculoneuritis.</p><p>Because the clinical manifestation of LNB is largely attributable to host immune responses, immune mediators in CSF offer attractive targets as biomarkers for diagnosis as well as markers of disease activity and resolution. LNB diagnosis is limited because CSF pleocytosis and clinical signs and symptoms of disease overlap with other neurologic conditions and are thus not unique to LNB. Moreover, borrelia-IT-Abs, although highly specific, take weeks to develop and thus offer limited sensitivity during early infection. In addition, once elevated, antibodies against borrelia can persist for years and may not be able to distinguish previous from current infection. Immune mediators such as CXCL13, which are presumably elevated before demonstratable cellular influx necessary for CSF pleocytosis and borrelia-IT-Ab-S, and decrease dramatically after antimicrobial therapy, appear to address these diagnostic limitations (<xref rid="R20" ref-type="bibr"><italic>20</italic></xref>). Indeed, CXCL13 has been proposed as an adjunct diagnostic marker for LNB (<xref rid="R19" ref-type="bibr"><italic>19</italic></xref>&#x02013;<xref rid="R26" ref-type="bibr"><italic>26</italic></xref>). However, studies in the United States and Europe have demonstrated that the diagnostic utility of CXCL13 is primarily limited to patients with definitive LNB who already meet the standard diagnostic criteria (CSF pleocytosis, <italic>Borrelia</italic> IT-<italic>Bb-</italic>Ab-S) (<xref rid="R18" ref-type="bibr"><italic>18</italic></xref>,<xref rid="R33" ref-type="bibr"><italic>33</italic></xref>,<xref rid="R34" ref-type="bibr"><italic>34</italic></xref>). Our findings underscore this point by demonstrating that CSF levels of CXCL13 are below the proposed 162 pg/mL diagnostic cutoff (<xref rid="R26" ref-type="bibr"><italic>26</italic></xref>) in most patients with suspected LNB (median CXCL13 levels 1 pg/mL) and even in many patients with PFP/meningitis (median CXCL13 levels 53 pg/mL). Our results suggest that CXCL13 diagnostic utility may be constrained to patients with meningoradiculoneuritis, a clinically identifiable condition. Nevertheless, because of their role in pathogenesis, immune mediators remain attractive targets as biomarkers, and new cytokines with greater discriminatory power than CXCL13 have been proposed in LNB (<xref rid="R16" ref-type="bibr"><italic>16</italic></xref>). As we have demonstrated, diagnostic suitability of these factors will require detailed studies of LNB patients with a range of well-defined clinical manifestations.</p><p>In addition to elevated immune responses, patients with borrelial meningoradiculoneuritis had a greater frequency and longer duration of constitutional symptoms than patients without radiculoneuritis. The most prevalent symptoms were sleep disturbance/insomnia, followed by fatigue, concentration disturbance, and memory disturbance, all of which could be attributed to sleeplessness resulting from pronounced radicular pain. However, these patients also had several other symptoms, such as low back pain, arthralgia, myalgia, and paresthesia, that are likely to have other causes, unrelated to sleeplessness. In contrast, patients with suspected LNB more often sought care for nonspecific symptoms such as headache, nausea, malaise, and vertigo. Thus, meningoradiculoneuritis is a distinct clinical entity distinguished not only by radicular pain but also by prevalence of several constitutional symptoms.</p><p>Alterations in the human genome have been implicated in maladaptive immune responses and severe Lyme borreliosis (<xref rid="R9" ref-type="bibr"><italic>9</italic></xref>&#x02013;<xref rid="R12" ref-type="bibr"><italic>12</italic></xref>). We previously demonstrated that a SNP (1805GG) in TLR1, a major sensor for <italic>Borrelia</italic>, alters host immune responses to infection and thereby the clinical course and outcome of Lyme borreliosis (<xref rid="R12" ref-type="bibr"><italic>12</italic></xref>). This SNP results in a transversion of thymine to guanine (1805T&#x0003e;1805G), causing an amino acid exchange of isoleucine for serine at position 602 in the transmembrane domain of the receptor, a constrained region likely to affect function. Indeed, the SNP results in decreased expression of TLR1 on cell surface and diminished downstream cytokine signaling in response to Pam<sub>3</sub>CSK<sub>4</sub>, a specific TLR1/2 agonist (<xref rid="R35" ref-type="bibr"><italic>35</italic></xref>&#x02013;<xref rid="R37" ref-type="bibr"><italic>37</italic></xref>). Paradoxically, in response to <italic>B. burgdorferi</italic> infection, this SNP is associated with excessive immune responses with marked levels of IFN-&#x003b3; and IFN-&#x003b3;&#x02013;inducible chemokines CXCL9 and CXCL10 in serum of patients with EM and even higher levels in joint fluid of those with postantibiotic (postinfectious) Lyme arthritis. This excessive inflammatory immune response was associated with highly symptomatic early infection in EM patients and with an elevated risk for postantibiotic chronic inflammatory Lyme arthritis (<xref rid="R12" ref-type="bibr"><italic>12</italic></xref>). In this study, we extended these concepts to patients with various manifestations of LNB. We show that patients with meningoradiculoneuritis have a significantly higher frequency of the TLR1&#x02013;1805GG SNP (OR&#x000a0;=&#x000a0;3.1; p = 0.03) and more symptoms (p&#x0003c;0.001) than those with other LNB manifestations. Moreover, patients with meningoradiculoneuritis also have heightened T-cell (namely Th1) and B-cell immune responses, consistent with the role of this SNP in excessive Th1 inflammation and more symptomatic disease in patients with EM or Lyme arthritis.</p><p>A limitation of this work is that, because genetic studies require separate consent, the TLR1&#x02013;1805GG analyses were performed in a different cohort of patients than those in whom the immune responses were tested; thus, we could not directly correlate the SNP genotype with the immune phenotype. Moreover, we based our study on a relatively small number of patients in each group. However, we should point out that this is an initial analysis of these concepts in LNB, and although small, these patient cohorts are well defined and are among the largest available. Finally, although the immune responses were elevated in CSF in patients with meningoradiculoneuritis as a group compared with those with PFP/meningitis, the levels of immune mediators varied in individual patients, and thus not every patient with radiculitis had higher CSF immune responses than did every patient with PFP/meningitis. Despite these limitations, these data support a link between TLR1&#x02013;1805GG SNP, maladaptive Th1 immunity, and disadvantageous clinical outcomes in several manifestations of Lyme borreliosis, including LNB. An effort is now underway to recruit additional patients to validate these genetic and immunologic results.</p><p>In summary, our study demonstrates that meningoradiculoneuritis is a distinct clinical entity with unique immune and genetic pathophysiology. In future studies, we hope to establish the functional link between the TLR1&#x02013;1805GG SNP, excessive site-specific T- and B-cell immune responses in CSF, and painful meningoradiculoneuritis. The findings from this study provide new considerations for the study of patients with meningoradiculoneuritis and LNB in general; further studies may help to improve accuracy of laboratory diagnosis.</p></sec></body><back><ack><title>Acknowledgments</title><p>We thank Graham Willsey for help with TLR1 genotyping. </p><p>This work was supported by the US National Institutes of Health (NIAID no. R21AI144916, and NIAMS no. K01AR062098) and the Massachusetts General Hospital Executive Committee on Research Interim Support Fund to K.S.; and by the Slovenian Research Agency (P3-0296, J3-1744, and J3-8195) to F.S. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or other funding agencies. Funding agencies were not involved in the design, conduct, or interpretation of the findings.</p><p>Author contributions: K.S., F.S., and K.O. designed the study. K.S., S.H., and M.K. conducted the experiments and the data analyses for this study. K.O., F.S., P.B., and T.R. examined patients with Lyme neuroborreliosis, made diagnoses, and collected clinical samples and clinical information. S.H., K.S., F.S., and K.O. wrote the manuscript. S.H., G.C., M.K., K.S., and L.L. performed the statistical analyses, contributed to generation of tables, and helped with the interpretation of the data. All authors reviewed and approved the manuscript.</p></ack><fn-group><fn fn-type="other"><p><italic>Suggested citation for this article</italic>: Ogrinc K, Hern&#x000e1;ndez SA, Korva M, Bogovic P, Rojko T, Lusa L, et al. Unique clinical, immune, and genetic signature in patients with borrelial meningoradiculoneuritis. Emerg Infect Dis. 2022 Apr [<italic>date cited</italic>]. <ext-link xlink:href="https://doi.org/10.3201/eid2804.211831" ext-link-type="uri">https://doi.org/10.3201/eid2804.211831</ext-link></p></fn><fn id="FN1"><label>1</label><p>Part of the research reported here was presented at the 31st European Congress of Clinical Microbiology &#x00026; Infectious Diseases (online), July 9<bold>&#x02013;</bold>12, 2021.</p></fn><fn id="FN2"><label>2</label><p>These first authors contributed equally to this article.</p></fn><fn id="FN3"><label>3</label><p>These senior authors contributed equally to this article.</p></fn></fn-group><bio id="d64e1167"><p>Dr. Ogrinc is an MD/PhD clinical researcher in the Department of Infectious Diseases at the University Medical Center Ljubljana, Slovenia. Her primary research interest is the clinical evaluation of patients with Lyme borreliosis with a focus on acrodermatitis chronica atrophicans and Lyme neuroborreliosis.</p></bio><ref-list><title>References</title><ref id="R1"><label>1. </label><mixed-citation publication-type="journal"><string-name><surname>Stanek</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Wormser</surname>
<given-names>GP</given-names></string-name>, <string-name><surname>Gray</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Strle</surname>
<given-names>F</given-names></string-name>. <article-title>Lyme borreliosis.</article-title>
<source>Lancet</source>. <year>2012</year>;<volume>379</volume>:<fpage>461</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(11)60103-7</pub-id><pub-id pub-id-type="pmid">21903253</pub-id></mixed-citation></ref><ref id="R2"><label>2. </label><mixed-citation publication-type="journal"><string-name><surname>Steere</surname>
<given-names>AC</given-names></string-name>, <string-name><surname>Strle</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Wormser</surname>
<given-names>GP</given-names></string-name>, <string-name><surname>Hu</surname>
<given-names>LT</given-names></string-name>, <string-name><surname>Branda</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Hovius</surname>
<given-names>JW</given-names></string-name>, <etal>et al.</etal>
<article-title>Lyme borreliosis.</article-title>
<source>Nat Rev Dis Primers</source>. <year>2016</year>;<volume>2</volume>:<fpage>16090</fpage>. <pub-id pub-id-type="doi">10.1038/nrdp.2016.90</pub-id><pub-id pub-id-type="pmid">27976670</pub-id></mixed-citation></ref><ref id="R3"><label>3. </label><mixed-citation publication-type="journal"><string-name><surname>Ogrinc</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Lusa</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Lotri&#x0010d;-Furlan</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Bogovi&#x0010d;</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Stupica</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Cerar</surname>
<given-names>T</given-names></string-name>, <etal>et al.</etal>
<article-title>Course and outcome of early European Lyme neuroborreliosis (Bannwarth syndrome): clinical and laboratory findings.</article-title>
<source>Clin Infect Dis</source>. <year>2016</year>;<volume>63</volume>:<fpage>346</fpage>&#x02013;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciw299</pub-id><pub-id pub-id-type="pmid">27161773</pub-id></mixed-citation></ref><ref id="R4"><label>4. </label><mixed-citation publication-type="journal"><string-name><surname>Stanek</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Strle</surname>
<given-names>F</given-names></string-name>. <article-title>Lyme borreliosis-from tick bite to diagnosis and treatment.</article-title>
<source>FEMS Microbiol Rev</source>. <year>2018</year>;<volume>42</volume>:<fpage>233</fpage>&#x02013;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1093/femsre/fux047</pub-id><pub-id pub-id-type="pmid">29893904</pub-id></mixed-citation></ref><ref id="R5"><label>5. </label><mixed-citation publication-type="other"><string-name><surname>Mygland</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Ljostad</surname>
<given-names>U</given-names></string-name>, <string-name><surname>Fingerle</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Rupprecht</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Schmutzhard</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Steiner</surname>
<given-names>I.</given-names></string-name> EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol. <year>2010</year>;17:8&#x02013;16, e1&#x02013;4. </mixed-citation></ref><ref id="R6"><label>6. </label><mixed-citation publication-type="journal"><string-name><surname>Ogrinc</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Lotri&#x0010d;-Furlan</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Maraspin</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Lusa</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Cerar</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Ru&#x0017e;i&#x0010d;-Sablji&#x0010d;</surname>
<given-names>E</given-names></string-name>, <etal>et al.</etal>
<article-title>Suspected early Lyme neuroborreliosis in patients with erythema migrans.</article-title>
<source>Clin Infect Dis</source>. <year>2013</year>;<volume>57</volume>:<fpage>501</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1093/cid/cit317</pub-id><pub-id pub-id-type="pmid">23667259</pub-id></mixed-citation></ref><ref id="R7"><label>7. </label><mixed-citation publication-type="journal"><string-name><surname>Cerar</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Strle</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Stupica</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Ruzic-Sabljic</surname>
<given-names>E</given-names></string-name>, <string-name><surname>McHugh</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Steere</surname>
<given-names>AC</given-names></string-name>, <etal>et al.</etal>
<article-title>Differences in genotype, clinical features, and inflammatory potential of Borrelia burgdorferi sensu stricto strains from Europe and the United States.</article-title>
<source>Emerg Infect Dis</source>. <year>2016</year>;<volume>22</volume>:<fpage>818</fpage>&#x02013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.3201/eid2205.151806</pub-id><pub-id pub-id-type="pmid">27088349</pub-id></mixed-citation></ref><ref id="R8"><label>8. </label><mixed-citation publication-type="journal"><string-name><surname>Grillon</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Scherlinger</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Boyer</surname>
<given-names>PH</given-names></string-name>, <string-name><surname>De Martino</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Perdriger</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Blasquez</surname>
<given-names>A</given-names></string-name>, <etal>et al.</etal>
<article-title>Characteristics and clinical outcomes after treatment of a national cohort of PCR-positive Lyme arthritis.</article-title>
<source>Semin Arthritis Rheum</source>. <year>2019</year>;<volume>48</volume>:<fpage>1105</fpage>&#x02013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/j.semarthrit.2018.09.007</pub-id><pub-id pub-id-type="pmid">30344080</pub-id></mixed-citation></ref><ref id="R9"><label>9. </label><mixed-citation publication-type="journal"><string-name><surname>Oosting</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Ter Hofstede</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Sturm</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Adema</surname>
<given-names>GJ</given-names></string-name>, <string-name><surname>Kullberg</surname>
<given-names>BJ</given-names></string-name>, <string-name><surname>van der Meer</surname>
<given-names>JW</given-names></string-name>, <etal>et al.</etal>
<article-title>TLR1/TLR2 heterodimers play an important role in the recognition of Borrelia spirochetes.</article-title>
<source>PLoS One</source>. <year>2011</year>;<volume>6</volume>:<elocation-id>e25998</elocation-id>. <pub-id pub-id-type="doi">10.1371/journal.pone.0025998</pub-id><pub-id pub-id-type="pmid">21998742</pub-id></mixed-citation></ref><ref id="R10"><label>10. </label><mixed-citation publication-type="journal"><string-name><surname>Steere</surname>
<given-names>AC</given-names></string-name>, <string-name><surname>Dwyer</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Winchester</surname>
<given-names>R</given-names></string-name>. <article-title>Association of chronic Lyme arthritis with HLA-DR4 and HLA-DR2 alleles.</article-title>
<source>N Engl J Med</source>. <year>1990</year>;<volume>323</volume>:<fpage>219</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1056/NEJM199007263230402</pub-id><pub-id pub-id-type="pmid">2078208</pub-id></mixed-citation></ref><ref id="R11"><label>11. </label><mixed-citation publication-type="journal"><string-name><surname>Steere</surname>
<given-names>AC</given-names></string-name>, <string-name><surname>Klitz</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Drouin</surname>
<given-names>EE</given-names></string-name>, <string-name><surname>Falk</surname>
<given-names>BA</given-names></string-name>, <string-name><surname>Kwok</surname>
<given-names>WW</given-names></string-name>, <string-name><surname>Nepom</surname>
<given-names>GT</given-names></string-name>, <etal>et al.</etal>
<article-title>Antibiotic-refractory Lyme arthritis is associated with HLA-DR molecules that bind a <italic>Borrelia burgdorferi</italic> peptide.</article-title>
<source>J Exp Med</source>. <year>2006</year>;<volume>203</volume>:<fpage>961</fpage>&#x02013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20052471</pub-id><pub-id pub-id-type="pmid">16585267</pub-id></mixed-citation></ref><ref id="R12"><label>12. </label><mixed-citation publication-type="journal"><string-name><surname>Strle</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Shin</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>Glickstein</surname>
<given-names>LJ</given-names></string-name>, <string-name><surname>Steere</surname>
<given-names>AC</given-names></string-name>. <article-title>Association of a Toll-like receptor 1 polymorphism with heightened Th1 inflammatory responses and antibiotic-refractory Lyme arthritis.</article-title>
<source>Arthritis Rheum</source>. <year>2012</year>;<volume>64</volume>:<fpage>1497</fpage>&#x02013;<lpage>507</lpage>. <pub-id pub-id-type="doi">10.1002/art.34383</pub-id><pub-id pub-id-type="pmid">22246581</pub-id></mixed-citation></ref><ref id="R13"><label>13. </label><mixed-citation publication-type="journal"><string-name><surname>Lochhead</surname>
<given-names>RB</given-names></string-name>, <string-name><surname>Strle</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Arvikar</surname>
<given-names>SL</given-names></string-name>, <string-name><surname>Weis</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>Steere</surname>
<given-names>AC</given-names></string-name>. <article-title>Lyme arthritis: linking infection, inflammation and autoimmunity.</article-title>
<source>Nat Rev Rheumatol</source>. <year>2021</year>;<volume>17</volume>:<fpage>449</fpage>&#x02013;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1038/s41584-021-00648-5</pub-id><pub-id pub-id-type="pmid">34226730</pub-id></mixed-citation></ref><ref id="R14"><label>14. </label><mixed-citation publication-type="journal"><string-name><surname>Sellati</surname>
<given-names>TJ</given-names></string-name>, <string-name><surname>Sahay</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Wormser</surname>
<given-names>GP</given-names></string-name>. <article-title>The Toll of a TLR1 polymorphism in lyme disease: a tale of mice and men.</article-title>
<source>Arthritis Rheum</source>. <year>2012</year>;<volume>64</volume>:<fpage>1311</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1002/art.34386</pub-id><pub-id pub-id-type="pmid">22246662</pub-id></mixed-citation></ref><ref id="R15"><label>15. </label><mixed-citation publication-type="journal"><string-name><surname>Eckman</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Pacheco-Quinto</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Herdt</surname>
<given-names>AR</given-names></string-name>, <string-name><surname>Halperin</surname>
<given-names>JJ</given-names></string-name>. <article-title>Neuroimmunomodulators in neuroborreliosis and Lyme encephalopathy.</article-title>
<source>Clin Infect Dis</source>. <year>2018</year>;<volume>67</volume>:<fpage>80</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciy019</pub-id><pub-id pub-id-type="pmid">29340592</pub-id></mixed-citation></ref><ref id="R16"><label>16. </label><mixed-citation publication-type="journal"><string-name><surname>Skogman</surname>
<given-names>BH</given-names></string-name>, <string-name><surname>Lager</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Brudin</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Jenmalm</surname>
<given-names>MC</given-names></string-name>, <string-name><surname>Tjernberg</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Henningsson</surname>
<given-names>AJ</given-names></string-name>. <article-title>Cytokines and chemokines in cerebrospinal fluid in relation to diagnosis, clinical presentation and recovery in children being evaluated for Lyme neuroborreliosis.</article-title>
<source>Ticks Tick Borne Dis</source>. <year>2020</year>;<volume>11</volume>:<elocation-id>101390</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.ttbdis.2020.101390</pub-id><pub-id pub-id-type="pmid">32019724</pub-id></mixed-citation></ref><ref id="R17"><label>17. </label><mixed-citation publication-type="journal"><string-name><surname>Henningsson</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Tjernberg</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Malmvall</surname>
<given-names>BE</given-names></string-name>, <string-name><surname>Forsberg</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Ernerudh</surname>
<given-names>J</given-names></string-name>. <article-title>Indications of Th1 and Th17 responses in cerebrospinal fluid from patients with Lyme neuroborreliosis: a large retrospective study.</article-title>
<source>J Neuroinflammation</source>. <year>2011</year>;<volume>8</volume>:<fpage>36</fpage>. <pub-id pub-id-type="doi">10.1186/1742-2094-8-36</pub-id><pub-id pub-id-type="pmid">21507218</pub-id></mixed-citation></ref><ref id="R18"><label>18. </label><mixed-citation publication-type="journal"><string-name><surname>Markowicz</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Sch&#x000f6;tta</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Kundi</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Bogovi&#x0010d;</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Ogrinc</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Strle</surname>
<given-names>F</given-names></string-name>, <etal>et al.</etal>
<article-title>CXCL13 concentrations in cerebrospinal fluid of patients with Lyme neuroborreliosis and other neurological disorders determined by Luminex and ELISA.</article-title>
<source>Ticks Tick Borne Dis</source>. <year>2018</year>;<volume>9</volume>:<fpage>1137</fpage>&#x02013;<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1016/j.ttbdis.2018.04.008</pub-id><pub-id pub-id-type="pmid">29705691</pub-id></mixed-citation></ref><ref id="R19"><label>19. </label><mixed-citation publication-type="journal"><string-name><surname>Hyt&#x000f6;nen</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Kortela</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Waris</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Puustinen</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Salo</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Oksi</surname>
<given-names>J</given-names></string-name>. <article-title>CXCL13 and neopterin concentrations in cerebrospinal fluid of patients with Lyme neuroborreliosis and other diseases that cause neuroinflammation.</article-title>
<source>J Neuroinflammation</source>. <year>2014</year>;<volume>11</volume>:<fpage>103</fpage>. <pub-id pub-id-type="doi">10.1186/1742-2094-11-103</pub-id><pub-id pub-id-type="pmid">24920219</pub-id></mixed-citation></ref><ref id="R20"><label>20. </label><mixed-citation publication-type="journal"><string-name><surname>Strle</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Henningsson</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Strle</surname>
<given-names>K</given-names></string-name>. <article-title>Diagnostic utility of CXCL13 in Lyme neuroborreliosis.</article-title>
<source>Clin Infect Dis</source>. <year>2021</year>;<volume>72</volume>:<fpage>1727</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciaa337</pub-id><pub-id pub-id-type="pmid">32221531</pub-id></mixed-citation></ref><ref id="R21"><label>21. </label><mixed-citation publication-type="journal"><string-name><surname>Skogman</surname>
<given-names>BH</given-names></string-name>, <string-name><surname>Lager</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Henningsson</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Tjernberg</surname>
<given-names>I</given-names></string-name>. <article-title>The recomBead Borrelia antibody index, CXCL13 and total IgM index for laboratory diagnosis of Lyme neuroborreliosis in children.</article-title>
<source>Eur J Clin Microbiol Infect Dis</source>. <year>2017</year>;<volume>36</volume>:<fpage>2221</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1007/s10096-017-3049-x</pub-id><pub-id pub-id-type="pmid">28730535</pub-id></mixed-citation></ref><ref id="R22"><label>22. </label><mixed-citation publication-type="journal"><string-name><surname>Henningsson</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Gyllemark</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Lager</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Skogman</surname>
<given-names>BH</given-names></string-name>, <string-name><surname>Tjernberg</surname>
<given-names>I</given-names></string-name>. <article-title>Evaluation of two assays for CXCL13 analysis in cerebrospinal fluid for laboratory diagnosis of Lyme neuroborreliosis.</article-title>
<source>APMIS</source>. <year>2016</year>;<volume>124</volume>:<fpage>985</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1111/apm.12596</pub-id><pub-id pub-id-type="pmid">27651242</pub-id></mixed-citation></ref><ref id="R23"><label>23. </label><mixed-citation publication-type="journal"><string-name><surname>Tjernberg</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Henningsson</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Eliasson</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Forsberg</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Ernerudh</surname>
<given-names>J</given-names></string-name>. <article-title>Diagnostic performance of cerebrospinal fluid chemokine CXCL13 and antibodies to the C6-peptide in Lyme neuroborreliosis.</article-title>
<source>J Infect</source>. <year>2011</year>;<volume>62</volume>:<fpage>149</fpage>&#x02013;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1016/j.jinf.2010.11.005</pub-id><pub-id pub-id-type="pmid">21087629</pub-id></mixed-citation></ref><ref id="R24"><label>24. </label><mixed-citation publication-type="journal"><string-name><surname>Borde</surname>
<given-names>JP</given-names></string-name>, <string-name><surname>Meier</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Fingerle</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Klier</surname>
<given-names>C</given-names></string-name>, <string-name><surname>H&#x000fc;bner</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Kern</surname>
<given-names>WV</given-names></string-name>. <article-title>CXCL13 may improve diagnosis in early neuroborreliosis with atypical laboratory findings.</article-title>
<source>BMC Infect Dis</source>. <year>2012</year>;<volume>12</volume>:<fpage>344</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2334-12-344</pub-id><pub-id pub-id-type="pmid">23228054</pub-id></mixed-citation></ref><ref id="R25"><label>25. </label><mixed-citation publication-type="journal"><string-name><surname>Lj&#x000f8;stad</surname>
<given-names>U</given-names></string-name>, <string-name><surname>Mygland</surname>
<given-names>&#x000c5;</given-names></string-name>. <article-title>CSF B - lymphocyte chemoattractant (CXCL13) in the early diagnosis of acute Lyme neuroborreliosis.</article-title>
<source>J Neurol</source>. <year>2008</year>;<volume>255</volume>:<fpage>782</fpage>. <pub-id pub-id-type="doi">10.1007/s00415-008-0974-8</pub-id><pub-id pub-id-type="pmid">27517589</pub-id></mixed-citation></ref><ref id="R26"><label>26. </label><mixed-citation publication-type="journal"><string-name><surname>Rupprecht</surname>
<given-names>TA</given-names></string-name>, <string-name><surname>Manz</surname>
<given-names>KM</given-names></string-name>, <string-name><surname>Fingerle</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Lechner</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Klein</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Pfirrmann</surname>
<given-names>M</given-names></string-name>, <etal>et al.</etal>
<article-title>Diagnostic value of cerebrospinal fluid CXCL13 for acute Lyme neuroborreliosis. A systematic review and meta-analysis.</article-title>
<source>Clin Microbiol Infect</source>. <year>2018</year>;<volume>24</volume>:<fpage>1234</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.cmi.2018.04.007</pub-id><pub-id pub-id-type="pmid">29674128</pub-id></mixed-citation></ref><ref id="R27"><label>27. </label><mixed-citation publication-type="journal"><string-name><surname>Stanek</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Fingerle</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Hunfeld</surname>
<given-names>KP</given-names></string-name>, <string-name><surname>Jaulhac</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Kaiser</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Krause</surname>
<given-names>A</given-names></string-name>, <etal>et al.</etal>
<article-title>Lyme borreliosis: clinical case definitions for diagnosis and management in Europe.</article-title>
<source>Clin Microbiol Infect</source>. <year>2011</year>;<volume>17</volume>:<fpage>69</fpage>&#x02013;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1111/j.1469-0691.2010.03175.x</pub-id><pub-id pub-id-type="pmid">20132258</pub-id></mixed-citation></ref><ref id="R28"><label>28. </label><mixed-citation publication-type="journal"><string-name><surname>Reiber</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Peter</surname>
<given-names>JB</given-names></string-name>. <article-title>Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs.</article-title>
<source>J Neurol Sci</source>. <year>2001</year>;<volume>184</volume>:<fpage>101</fpage>&#x02013;<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/S0022-510X(00)00501-3</pub-id><pub-id pub-id-type="pmid">11239944</pub-id></mixed-citation></ref><ref id="R29"><label>29. </label><mixed-citation publication-type="journal"><string-name><surname>Postic</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Assous</surname>
<given-names>MV</given-names></string-name>, <string-name><surname>Grimont</surname>
<given-names>PA</given-names></string-name>, <string-name><surname>Baranton</surname>
<given-names>G</given-names></string-name>. <article-title>Diversity of <italic>Borrelia burgdorferi</italic> sensu lato evidenced by restriction fragment length polymorphism of rrf (5S)-rrl (23S) intergenic spacer amplicons.</article-title>
<source>Int J Syst Bacteriol</source>. <year>1994</year>;<volume>44</volume>:<fpage>743</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1099/00207713-44-4-743</pub-id><pub-id pub-id-type="pmid">7981102</pub-id></mixed-citation></ref><ref id="R30"><label>30. </label><mixed-citation publication-type="journal"><string-name><surname>Ruzi&#x00107;-Sablji&#x00107;</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Maraspin</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Lotric-Furlan</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Jurca</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Logar</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Pikelj-Pecnik</surname>
<given-names>A</given-names></string-name>, <etal>et al.</etal>
<article-title>Characterization of <italic>Borrelia burgdorferi</italic> sensu lato strains isolated from human material in Slovenia.</article-title>
<source>Wien Klin Wochenschr</source>. <year>2002</year>;<volume>114</volume>:<fpage>544</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">12422599</pub-id></mixed-citation></ref><ref id="R31"><label>31. </label><mixed-citation publication-type="journal"><string-name><surname>Ruzi&#x00107;-Sablji&#x00107;</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Zore</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Strle</surname>
<given-names>F</given-names></string-name>. <article-title>Characterization of <italic>Borrelia burgdorferi</italic> sensu lato isolates by pulsed-field gel electrophoresis after MluI restriction of genomic DNA.</article-title>
<source>Res Microbiol</source>. <year>2008</year>;<volume>159</volume>:<fpage>441</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.resmic.2008.05.005</pub-id><pub-id pub-id-type="pmid">18586084</pub-id></mixed-citation></ref><ref id="R32"><label>32. </label><mixed-citation publication-type="journal"><string-name><surname>Gyllemark</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Forsberg</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Ernerudh</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Henningsson</surname>
<given-names>AJ</given-names></string-name>. <article-title>Intrathecal Th17- and B cell-associated cytokine and chemokine responses in relation to clinical outcome in Lyme neuroborreliosis: a large retrospective study.</article-title>
<source>J Neuroinflammation</source>. <year>2017</year>;<volume>14</volume>:<fpage>27</fpage>. <pub-id pub-id-type="doi">10.1186/s12974-017-0789-6</pub-id><pub-id pub-id-type="pmid">28148307</pub-id></mixed-citation></ref><ref id="R33"><label>33. </label><mixed-citation publication-type="journal"><string-name><surname>Eckman</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Clausen</surname>
<given-names>DM</given-names></string-name>, <string-name><surname>Herdt</surname>
<given-names>AR</given-names></string-name>, <string-name><surname>Pacheco-Quinto</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Halperin</surname>
<given-names>JJ</given-names></string-name>. <article-title>Specificity and diagnostic utility of cerebrospinal fluid CXCL13 in Lyme neuroborreliosis.</article-title>
<source>Clin Infect Dis</source>. <year>2021</year>;<volume>72</volume>:<fpage>1719</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciaa335</pub-id><pub-id pub-id-type="pmid">32221538</pub-id></mixed-citation></ref><ref id="R34"><label>34. </label><mixed-citation publication-type="journal"><string-name><surname>Cerar</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Ogrinc</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Lotric-Furlan</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Kobal</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Levicnik-Stezinar</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Strle</surname>
<given-names>F</given-names></string-name>, <etal>et al.</etal>
<article-title>Diagnostic value of cytokines and chemokines in lyme neuroborreliosis.</article-title>
<source>Clin Vaccine Immunol</source>. <year>2013</year>;<volume>20</volume>:<fpage>1578</fpage>&#x02013;<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1128/CVI.00353-13</pub-id><pub-id pub-id-type="pmid">23945160</pub-id></mixed-citation></ref><ref id="R35"><label>35. </label><mixed-citation publication-type="journal"><string-name><surname>Hawn</surname>
<given-names>TR</given-names></string-name>, <string-name><surname>Misch</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Dunstan</surname>
<given-names>SJ</given-names></string-name>, <string-name><surname>Thwaites</surname>
<given-names>GE</given-names></string-name>, <string-name><surname>Lan</surname>
<given-names>NT</given-names></string-name>, <string-name><surname>Quy</surname>
<given-names>HT</given-names></string-name>, <etal>et al.</etal>
<article-title>A common human TLR1 polymorphism regulates the innate immune response to lipopeptides.</article-title>
<source>Eur J Immunol</source>. <year>2007</year>;<volume>37</volume>:<fpage>2280</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1002/eji.200737034</pub-id><pub-id pub-id-type="pmid">17595679</pub-id></mixed-citation></ref><ref id="R36"><label>36. </label><mixed-citation publication-type="journal"><string-name><surname>Misch</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Hawn</surname>
<given-names>TR</given-names></string-name>. <article-title>Toll-like receptor polymorphisms and susceptibility to human disease.</article-title>
<source>Clin Sci (Lond)</source>. <year>2008</year>;<volume>114</volume>:<fpage>347</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1042/CS20070214</pub-id><pub-id pub-id-type="pmid">18230059</pub-id></mixed-citation></ref><ref id="R37"><label>37. </label><mixed-citation publication-type="journal"><string-name><surname>Johnson</surname>
<given-names>CM</given-names></string-name>, <string-name><surname>Lyle</surname>
<given-names>EA</given-names></string-name>, <string-name><surname>Omueti</surname>
<given-names>KO</given-names></string-name>, <string-name><surname>Stepensky</surname>
<given-names>VA</given-names></string-name>, <string-name><surname>Yegin</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Alpsoy</surname>
<given-names>E</given-names></string-name>, <etal>et al.</etal>
<article-title>Cutting edge: A common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy.</article-title>
<source>J Immunol</source>. <year>2007</year>;<volume>178</volume>:<fpage>7520</fpage>&#x02013;<lpage>4</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.178.12.7520</pub-id><pub-id pub-id-type="pmid">17548585</pub-id></mixed-citation></ref></ref-list></back></article>